MedTrace Logo

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02436707 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2026-04-20

No results posted yet for this study

Summary

The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

Conditions

Interventions

DRUG

Ibrutinib

DRUG

Rituximab

DRUG

Gemcitabine

DRUG

Dexamethasone

DRUG

Cisplatin

DRUG

Mesna

DRUG

Cyclophosphamide

DRUG

Etoposide

DRUG

G-CSF

DRUG

Selinexor

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • Karyopharm Therapeutics Inc

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Michael Crump · Univ. Health Network-OCI/Princess Margaret Hospital, Toronto ON Canada

  • John Kuruvilla · Univ. Health Network-Princess Margaret Hospital, Toronto ON Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-27
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02436707 on ClinicalTrials.gov